NVO Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of -64.14%. Novo Nordisk A/S's return on equity of 68.76% beat Evaxion AS's return on equity of --.

Novo Nordisk A/S has a consensus price target of $53.33, signalling upside risk potential of 3.33%. On the other hand Evaxion AS has an analysts' consensus of $14.19 which suggests that it could grow by 188.36%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.35%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Evaxion AS quarterly revenues of $37.5K. Novo Nordisk A/S's net income of $3.1B is higher than Evaxion AS's net income of -$4.9M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 15.03x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.92x versus 3.30x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Omeros Corp. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 68.76% beat Omeros Corp.'s return on equity of --.

Novo Nordisk A/S has a consensus price target of $53.33, signalling upside risk potential of 3.33%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 220%. Given that Omeros Corp. has higher upside potential than Novo Nordisk A/S, analysts believe Omeros Corp. is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.35%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Omeros Corp. quarterly revenues of --. Novo Nordisk A/S's net income of $3.1B is higher than Omeros Corp.'s net income of -$21.2M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 15.03x while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.92x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of 38.89%. Novo Nordisk A/S's return on equity of 68.76% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Novo Nordisk A/S has a consensus price target of $53.33, signalling upside risk potential of 3.33%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 0.6%. Given that Novo Nordisk A/S has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Novo Nordisk A/S is more attractive than Regeneron Pharmaceuticals, Inc..

Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.35%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Novo Nordisk A/S's net income of $3.1B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Novo Nordisk A/S's price-to-earnings ratio is 15.03x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.92x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 68.76% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Novo Nordisk A/S has a consensus price target of $53.33, signalling upside risk potential of 3.33%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 156.49%. Given that Viking Therapeutics, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Viking Therapeutics, Inc. is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.35%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Novo Nordisk A/S's net income of $3.1B is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 15.03x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.92x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.